×
About 6,985 results

ALLMedicine™ Hypercalcemia Center

Research & Reviews  1,819 results

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04634552

Aug 12th, 2022 - Multiple myeloma is a malignant plasma cell disorder characterized by osteolytic lesions, increased susceptibility to infections, hypercalcemia, and renal failure. Talquetamab is a humanized immunoglobulin G4 proline, alanine, alanine (IgG4PAA) bi...

Studies of Inherited Diseases of Metabolism
https://clinicaltrials.gov/ct2/show/NCT00001345

Aug 12th, 2022 - Familial multiple endocrine neoplasia type 1 (MEN1), familial hypocalciuric (or familial benign) hypercalcemia (FHH), hyperparathyroidism - jaw tumor syndrome (HPT-JT), other causes of familial isolated hyperparathyroidism (FIHP), and pseudohypopa...

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04108195

Aug 12th, 2022 - Multiple myeloma is a malignant plasma cell disorder characterized by osteolytic lesions, increased susceptibility to infections, hypercalcemia, and renal failure. Overall rationale of study is that daratumumab in combination with talquetamab or t...

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04933539

Aug 12th, 2022 - Background: Smoldering multiple myeloma (SMM) is a precursor condition to MM defined by the clinical parameters of M-protein >=3.0 g/dL or bone marrow plasma cells >=10%, and absence of end organ disease. Patients with high-risk SMM have a risk of...

Parathyroid hormone-related protein (PTHrP) and malignancy.
https://doi.org/10.1016/bs.vh.2022.03.002
Vitamins and Hormones; Grunbaum A, Kremer R

Aug 12th, 2022 - PTHrP (parathyroid hormone related protein) is an important mediator of malignancy-related tumor progression and hypercalcemia that shares considerable homology and functionality with parathyroid hormone. In this chapter, we review what has been e...

see more →

Guidelines  4 results

Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494249
Journal of Clinical Oncology : Official Journal of the Am... Cook LB, Fuji S et. al.

Jan 19th, 2019 - Adult T-cell leukemia-lymphoma (ATL) is a distinct mature T-cell malignancy caused by chronic infection with human T-lymphotropic virus type 1 with diverse clinical features and prognosis. ATL remains a challenging disease as a result of its diver...

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0023
Journal of the National Comprehensive Cancer Network : JN... Kumar SK, Callander NS et. al.

Feb 12th, 2017 - Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal damage, a hallmark of multiple myeloma. Other MM-r...

SEOM guidelines on hydroelectrolytic disorders.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239780
Clinical & Translational Oncology : Official Publication ... De las Peñas R, Escobar Y et. al.

Oct 12th, 2014 - Hydroelectrolytic disorders are one of the most common metabolic complications in cancer patients. Although often metabolic alterations affecting various ions are part of the manifestations of the oncological disease, even in the form of paraneopl...

Vitamin D Toxicity - StatPearls
https://www.ncbi.nlm.nih.gov/books/NBK557876/
StatPearls Asif A, Farooq N.

Vitamin D is a fat-soluble vitamin that is found in some animal food products and is also synthesized in the human body via exposure to the sun. Toxicity of vitamin D leads to hypercalcemia and imbalance in the regulation of bone metabolism; the r...

see more →

Drugs  558 results see all →

Clinicaltrials.gov  157 results

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04634552

Aug 12th, 2022 - Multiple myeloma is a malignant plasma cell disorder characterized by osteolytic lesions, increased susceptibility to infections, hypercalcemia, and renal failure. Talquetamab is a humanized immunoglobulin G4 proline, alanine, alanine (IgG4PAA) bi...

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04933539

Aug 12th, 2022 - Background: Smoldering multiple myeloma (SMM) is a precursor condition to MM defined by the clinical parameters of M-protein >=3.0 g/dL or bone marrow plasma cells >=10%, and absence of end organ disease. Patients with high-risk SMM have a risk of...

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04108195

Aug 12th, 2022 - Multiple myeloma is a malignant plasma cell disorder characterized by osteolytic lesions, increased susceptibility to infections, hypercalcemia, and renal failure. Overall rationale of study is that daratumumab in combination with talquetamab or t...

Studies of Inherited Diseases of Metabolism
https://clinicaltrials.gov/ct2/show/NCT00001345

Aug 12th, 2022 - Familial multiple endocrine neoplasia type 1 (MEN1), familial hypocalciuric (or familial benign) hypercalcemia (FHH), hyperparathyroidism - jaw tumor syndrome (HPT-JT), other causes of familial isolated hyperparathyroidism (FIHP), and pseudohypopa...

Denosumab for Smoldering Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT03839459

Aug 10th, 2022 - This is an open label, Phase II trial of denosumab 120mg subcutaneous (SC) for patients with smoldering multiple myeloma (SMM). Subjects will be recruited from the James P. Wilmot Cancer Center, University of Rochester in Rochester, New York. Pati...

see more →

News  245 results

Agent Orange Exposure, Transformation From MGUS to Multiple Myeloma, and Outcomes in Veterans
https://www.mdedge.com/fedprac/avaho/article/256893/multiple-myeloma/agent-orange-exposure-transformation-mgus-multiple
Jyothi Dodlapati, MD, James A. Hall, DO et. al.

Aug 9th, 2022 - Multiple myeloma (MM) accounts for 1% to 2% of all cancers and slightly more than 17% of hematologic malignancies in the United States. 1 MM is characterized by the neoplastic proliferation of immunoglobulin (Ig)-producing plasma cells with ≥ 10% c.

Nab-Paclitaxel Plus Pembrolizumab Produces Promising Responses in Advanced Urothelial Cancer
https://www.onclive.com/view/nab-paclitaxel-plus-pembrolizumab-produces-promising-responses-in-advanced-urothelial-cancer

May 2nd, 2022 - The combination of nab-paclitaxel (Abraxane) and pembrolizumab (Keytruda) produced an encouraging overall response rate (ORR) with manageable safety in patients with advanced urothelial cancer who were refractory to platinum-based chemotherapy or ...

FDA Grants Orphan Drug Designation to Toripalimab for Small Cell Lung Cancer
https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-toripalimab-for-small-cell-lung-cancer

Apr 21st, 2022 - The FDA has granted an orphan drug designation to the PD-1 inhibitor toripalimab as a potential therapeutic option for patients with small cell lung cancer (SCLC), according to an announcement from Coherus BioSciences, Inc. and Shanghai Junshi Bio...

Surgery Shows No Survival, Morbidity Benefit for Mild Hyperparathyroidism
https://www.medscape.com/viewarticle/972299

Apr 18th, 2022 - Patients who receive parathyroidectomy for mild primary hyperparathyroidism show no benefits in survival or morbidity, including fractures, cancer, or cardiovascular outcomes over more than 10 years, when compared with those not receiving the surg...

Myeloma at Younger Age Shortens Lifespan Despite Lengthy Overall Survival
https://www.medpagetoday.com/hematologyoncology/myeloma/96496

Jan 4th, 2022 - Multiple myeloma at a younger age did not portend more aggressive disease or worse outcomes but significantly shortened lifespan as compared with the general population without myeloma, according to one of the largest studies of its kind. Over a 1...

see more →

Patient Education  11 results see all →